Oncolytics Biotech (TSE:ONC) Director Bernd Robert Seizinger Acquires 60,000 Shares of Stock

Oncolytics Biotech Inc. (TSE:ONC) Director Bernd Robert Seizinger bought 60,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The stock was purchased at an average cost of C$1.14 per share, for a total transaction of C$68,400.00. Following the transaction, the director owned 526,991 shares in the company, valued at C$600,769.74. The trade was a 12.85% increase in their position.

Bernd Robert Seizinger also recently made the following trade(s):

• On Thursday, February 12th, Bernd Robert Seizinger purchased 40,000 shares of Oncolytics Biotech stock. The shares were purchased at an average cost of C$1.17 per share, with a total value of C$46,800.00.

Oncolytics Biotech Stock Performance

Shares of TSE ONC opened at C$14.90 on Friday. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The stock’s fifty day moving average price is C$14.90 and its two-hundred day moving average price is C$13.03. Oncolytics Biotech Inc. has a one year low of C$0.44 and a one year high of C$2.08. The firm has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech (TSE:ONC) last announced its earnings results on Wednesday, November 12th. The company reported C($0.14) EPS for the quarter. On average, equities analysts forecast that Oncolytics Biotech Inc. will post -0.41 EPS for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.